Clinical trial ACTRN12619000673145
Status: Recruiting (according to the registry)Phase 2Latest change: Source: ANZCTR (Australia, New Zealand) (via WHO ICTRP)
What's on this page?
This record’s status may be out of date
The trial was registered in May 6, 2019 and still shows as "recruiting" in the registry. Status information in other countries’ registries is often not updated; the trial may have ended or stopped. For current information, check the record itself.
Information in the record
Original title: Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion Syndrome
- Record number
- ACTRN12619000673145
- Registry
- ANZCTR (Australia, New Zealand) (via WHO ICTRP)
- Status
- Recruiting (according to the registry)
- Type and phase
- Clinical trial, phase 2
- Participants
- Target: 20
- Condition (as registered)
- Pediatric 22q11.2 deletion syndrome, Neurological - Other neurological disorders, Mental Health - Psychosis and personality disorders, Human Genetics and Inherited Disorders - Other human genetics and inherited disorders
- Countries
- Australia
- Topic in the guide
- Schizophrenia
Timeline
According to the ANZCTR (Australia, New Zealand) (via WHO ICTRP) record. Future dates are the investigator’s estimates and may change.
- Registration: May 6, 2019
History
We check the record once a month via WHO ICTRP; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Recruiting.
Results
No results have been published yet. When they are, they will appear here. A trial being under way does not mean CBD works for this condition; only the results can show that.
All ongoing trials · Schizophrenia: guide page · Thinking of taking part? Which specialist to see